A Calderón-Larrañaga1, J M Abad-Díez2, L A Gimeno-Feliu3, J Marta-Moreno4, F González-Rubio5, M Clerencia-Sierra6, B Poblador-Plou7, A Poncel-Falcó8, A Prados-Torres7. 1. EpiChron Research Group on Chronic Diseases, Aragon Health Sciences Institute (IACS), IIS Aragon, Miguel Servet University Hospital, Paseo Isabel La Católica 1-3, 50009 Zaragoza, Spain. Electronic address: acalderon.iacs@aragon.es. 2. EpiChron Research Group on Chronic Diseases, Aragon Health Sciences Institute (IACS), IIS Aragon, Miguel Servet University Hospital, Paseo Isabel La Católica 1-3, 50009 Zaragoza, Spain; Dept. of Health, Welfare and Family, DG Planning and Assurance, Government of Aragon, Vía Univérsitas 36, 50009 Zaragoza, Spain. 3. EpiChron Research Group on Chronic Diseases, Aragon Health Sciences Institute (IACS), IIS Aragon, Miguel Servet University Hospital, Paseo Isabel La Católica 1-3, 50009 Zaragoza, Spain; San Pablo Health Centre, Aragon Health Service (SALUD), C/Aguadores 7, 50003 Zaragoza, Spain. 4. EpiChron Research Group on Chronic Diseases, Aragon Health Sciences Institute (IACS), IIS Aragon, Miguel Servet University Hospital, Paseo Isabel La Católica 1-3, 50009 Zaragoza, Spain; Miguel Servet University Hospital, Department of Neurology, Aragon Health Service (SALUD), Paseo Isabel La Católica 1-3, 50009 Zaragoza, Spain. 5. EpiChron Research Group on Chronic Diseases, Aragon Health Sciences Institute (IACS), IIS Aragon, Miguel Servet University Hospital, Paseo Isabel La Católica 1-3, 50009 Zaragoza, Spain; Delicias Sur Health Centre, Aragon Health Service (SALUD), C/Manuel Dronda 1, 50009 Zaragoza, Spain. 6. EpiChron Research Group on Chronic Diseases, Aragon Health Sciences Institute (IACS), IIS Aragon, Miguel Servet University Hospital, Paseo Isabel La Católica 1-3, 50009 Zaragoza, Spain; Socio-Sanitary Assessment Unit, Miguel Servet University Hospital, Aragon Health Service (SALUD), Paseo Isabel La Católica 1-3, 50009 Zaragoza, Spain. 7. EpiChron Research Group on Chronic Diseases, Aragon Health Sciences Institute (IACS), IIS Aragon, Miguel Servet University Hospital, Paseo Isabel La Católica 1-3, 50009 Zaragoza, Spain. 8. EpiChron Research Group on Chronic Diseases, Aragon Health Sciences Institute (IACS), IIS Aragon, Miguel Servet University Hospital, Paseo Isabel La Católica 1-3, 50009 Zaragoza, Spain; Zaragoza-Sector III Primary Care Directorate, Aragon Health Service (SALUD), C/Condes de Aragón 30, 50009 Zaragoza, Spain.
Abstract
AIM: To identify patterns of health care use among diabetic patients with multimorbidity across primary, specialised, hospital and emergency care, depending on their type of chronic comorbidity. METHODS: Longitudinal study of a population-based retrospective cohort conformed by adult patients with type-2 diabetes assigned to any of the primary care centres in Aragon during 2010 and 2011 (n=65,716). Negative binomial regressions were run to model the effect of the type of comorbidity on the number of visits to each level of care. Comorbidities were classified as concordant, discordant or mental based on expert consensus and depending on whether they shared the same overall pathophysiologic risk profile and disease management plan designed for type-2 diabetes. RESULTS: Mental comorbidity was independently associated with total and unplanned admissions (incidence rate ratio [IRR]:1.25; 95% confidence interval [CI]:1.12-1.39, IRR:1.21; 95% CI:1.06-1.39), average length of stay (IRR:1.47; 95% CI:1.25-1.73), and total and priority emergency room visits (IRR:1.26; 95% CI:1.17-1.35, IRR:1.30; 95% CI:1.18-1.42). Patients with discordant comorbidities showed the strongest associations with the number of visits to specialists (IRR:1.38; 95% CI:1.33-1.43) and to different specialties (IRR:1.36; 95% CI:1.32-1.39). Differences regarding GP visits were lower but still significant for patients with discordant comorbidity (IRR:1.08; 95% CI:1.06-1.11), but especially for those with mental comorbidity (IRR:1.17; 95% CI:1.14-1.21). CONCLUSION: In patients with type-2 diabetes, the coexistence of mental comorbidity significantly increases the use of unplanned hospital services, and discordant comorbidities have an important effect on specialised care use. Differences with respect to primary care use are not as prominent.
AIM: To identify patterns of health care use among diabeticpatients with multimorbidity across primary, specialised, hospital and emergency care, depending on their type of chronic comorbidity. METHODS: Longitudinal study of a population-based retrospective cohort conformed by adult patients with type-2 diabetes assigned to any of the primary care centres in Aragon during 2010 and 2011 (n=65,716). Negative binomial regressions were run to model the effect of the type of comorbidity on the number of visits to each level of care. Comorbidities were classified as concordant, discordant or mental based on expert consensus and depending on whether they shared the same overall pathophysiologic risk profile and disease management plan designed for type-2 diabetes. RESULTS: Mental comorbidity was independently associated with total and unplanned admissions (incidence rate ratio [IRR]:1.25; 95% confidence interval [CI]:1.12-1.39, IRR:1.21; 95% CI:1.06-1.39), average length of stay (IRR:1.47; 95% CI:1.25-1.73), and total and priority emergency room visits (IRR:1.26; 95% CI:1.17-1.35, IRR:1.30; 95% CI:1.18-1.42). Patients with discordant comorbidities showed the strongest associations with the number of visits to specialists (IRR:1.38; 95% CI:1.33-1.43) and to different specialties (IRR:1.36; 95% CI:1.32-1.39). Differences regarding GP visits were lower but still significant for patients with discordant comorbidity (IRR:1.08; 95% CI:1.06-1.11), but especially for those with mental comorbidity (IRR:1.17; 95% CI:1.14-1.21). CONCLUSION: In patients with type-2 diabetes, the coexistence of mental comorbidity significantly increases the use of unplanned hospital services, and discordant comorbidities have an important effect on specialised care use. Differences with respect to primary care use are not as prominent.
Authors: Angela Y Chang; F Xavier Gómez-Olivé; Jennifer Manne-Goehler; Alisha N Wade; Stephen Tollman; Thomas A Gaziano; Joshua A Salomon Journal: Bull World Health Organ Date: 2018-10-31 Impact factor: 9.408
Authors: Meryem Cicek; James Buckley; Jonathan Pearson-Stuttard; Edward W Gregg Journal: Endocrinol Metab Clin North Am Date: 2021-09 Impact factor: 4.741
Authors: Rose J Geurten; Jeroen N Struijs; Arianne M J Elissen; Henk J G Bilo; Chantal van Tilburg; Dirk Ruwaard Journal: Pharmacoecon Open Date: 2021-12-04
Authors: Tora Grauers Willadsen; Anna Bebe; Rasmus Køster-Rasmussen; Dorte Ejg Jarbøl; Ann Dorrit Guassora; Frans Boch Waldorff; Susanne Reventlow; Niels de Fine Olivarius Journal: Scand J Prim Health Care Date: 2016-03-08 Impact factor: 2.581
Authors: A Prados-Torres; B Poblador-Plou; A Gimeno-Miguel; A Calderón-Larrañaga; A Poncel-Falcó; L A Gimeno-Feliú; F González-Rubio; C Laguna-Berna; J Marta-Moreno; M Clerencia-Sierra; M Aza-Pascual-Salcedo; A C Bandrés-Liso; C Coscollar-Santaliestra; V Pico-Soler; J M Abad-Díez Journal: Int J Epidemiol Date: 2018-04-01 Impact factor: 7.196
Authors: Roseanne O Yeung; Jing-Heng Cai; Yuying Zhang; Andrea O Luk; Jun-Hao Pan; Junmei Yin; Risa Ozaki; Alice P S Kong; Ronald Ma; Wing-Yee So; Chiu Chi Tsang; K P Lau; Edwin Fisher; Williams Goggins; Brian Oldenburg; Julianna Chan Journal: Clin Diabetes Endocrinol Date: 2018-03-07